GENB
Generate Biomedicines, Inc.
NASDAQ · Financial Services · Asset Management · US
$14.46
−8.33%Oct 13, 2026, 20:30 UTC
Generate Biomedicines, Inc. and Zealand Pharma A/S entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.
Source:Oct 1, 2026, 11:00 UTC
Roswell Park Comprehensive Cancer Center and Generate Biomedicines launched an exclusive clinical trial of the AI-engineered CAR T therapy GB-5267 for ovarian cancer, with the first patient treated.
Source:Aug 25, 2026, 15:22 UTC
Generate Biomedicines Inc's post-IPO lock-up period is set to expire on Wednesday, allowing insiders, early investors, and major shareholders to sell shares from its $400 million IPO.
Source:Aug 6, 2026, 11:00 UTC
Generate Biomedicines Inc. reported its second quarter 2026 financial results, including cash, cash equivalents, and marketable securities of approximately $457.4 million as of June 30, 2026.
Source: